#Henlius announced its annual results for 2025: revenue increased 16.5% to RMB 6.6666B, net profit reached RMB 0.8270B, and R&D investment grew 35.4%. With ex-China revenue doubling and approvals for 10 products across 60 regions, Henlius advances innovation and globalization.
Henlius announces that China’s National Medical Products Administration has approved the Investigational New Drug application for HLX316. This potential first‑in‑class therapy is designed to help the immune system recognize and fight advanced or metastatic solid tumors.
In 2025, Fosun steadfastly focused on its core businesses.
Twelve milestones, like twelve signposts, marked every step of Fosun’s ascent throughout the year.
2026, Advancing into the New
#FosunStory
https://t.co/L3b83m3vtK
Sonic Labs has invested in FinChain, an institution-grade RWA provider.
With FinChain, we’re advancing our mission to be the settlement layer for the future of finance.
📈 RWA Issuance on Sonic
🏦 Institution-Ready Rails
⚡ Composability w/ DeFi
🔗 https://t.co/n3JA2S76v4
🛸「FORESIGHT 2024 」年度峰会圆桌论坛🛸
圆桌主题: 「ETF 如何影响加密货币市场?」
圆桌嘉宾:
Patrick Pan @osldotcom , Chairman of the Board;
Thomas Zhu 华夏基金(香港), Head of Digital Assets;
Chen Zhao 复兴财富, Digital Assests Director;
Andre Skauradssun @gmci_ , Head of Research
@lawmaster @TheBlock__ , CEO
更多大会议程信息将逐一揭晓,请密切关注:
https://t.co/rKjSwNIVWw